Vanda Pharmaceuticals Inc.
VNDA
NASDAQ·Healthcare·Biotechnology·Mkt cap $326.5M
$5.43
▲ +1.69%
P/E
-1.17
Mkt Cap
$326.5M
52-Wk Range
$4.27–$9.94
52-Week Range
$4.27 - $9.94
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 19.3% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Established commercial infrastructure with FDA-approved products generating revenue
- Diverse pipeline addressing multiple high-unmet-need indications with differentiated mechanisms of action
- Expertise in rare and orphan diseases with less competitive landscapes and potential for premium pricing
- Multiple expansion opportunities for existing products across new indications and patient populations
Bear Case
1 risk
- Low volatility (beta 0.6).
Growth
Moderate growth ahead
Pipeline advancement: Multiple candidates in clinical development across psychiatry, dermatology, and oncology
Value
Deep value opportunity - significant discount to Biotech & Therapeutics peers
Momentum
Weak
-8.6% over 3m
Quality
Excellent
Mixed fundamentals
Dividend
None
No dividend
Smart-money signal
Who's buying VNDA right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 4, 2026
AUG 5, 2026
Reported EPS of -$1.04 vs -$0.58 consensus (-78.5% surprise). Revenue of $50.5M vs $61.9M expected (-18.4%).
EPS surprise · last 4Q
0 of 1 beats
Estimate
Actual
Q3 26
-78.5%
Revenue trend · last 8Q
—
+17%
+5%
+4%
+18%
+8%
+3%
-4%
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$47.7M
$53.2M
$50.0M
$52.6M
$56.3M
$57.2M
$51.7M
$50.5M
Margins · last 8Q
Gross
-92.2%
Operating
-126.3%
Profit
-123.7%
Wall Street consensus
1 analyst · 100% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
100%
Hold
0%
Sell
0%
Median Price Target
—
Latest: HC Wainwright · Aug 10, 2026
vs Industry
How VNDA stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related